Surrey Heartlands

Joint Formulary & PAD

Montelukast - Asthma

You are here : Home > Formulary Search > Montelukast - Asthma

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Chewable tablets
  • Sachets (granules)
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :

Documentation

Webpage
NICE NG80 - Asthma-diagnosis-monitoring-and-chronic-asthma-management

PAD Profile

ChemicalSubstance :
Montelukast
Indication :
Asthma
Group Name :
Keywords :
Leukotriene receptor antagonists, LTRAs
Brand Names Include :
Singulair
Important Information :
https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Asthma
Supporting Documents :
1

Other Indications

Below are listed other indications that Montelukast is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Asthma.

Committee Recommendations (1)

06 Mar 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Montelukast may be an appropriate first-line addition to ICS (particularly if atopy or allergic component).

Prescribe generically (the brand Singulair was assigned a BLACK traffic light status by the PCN in May 2017)

The guidelines for Asthma can be found below